Intravitreal sustained-release ganciclovir implants for severe bilateral cytomegalovirus retinitis after stem cell transplantation
Article first published online: 20 MAR 2002
Acta Ophthalmologica Scandinavica
Volume 80, Issue 1, pages 101–104, February 2002
How to Cite
Ghosh, F., Hansson, L.-J., Bynke, G. and Békássy, A. N. (2002), Intravitreal sustained-release ganciclovir implants for severe bilateral cytomegalovirus retinitis after stem cell transplantation. Acta Ophthalmologica Scandinavica, 80: 101–104. doi: 10.1034/j.1600-0420.2002.800121.x
- Issue published online: 20 MAR 2002
- Article first published online: 20 MAR 2002
- Received on March 16th, 2001.Accepted on September 19th, 2001.
- acute lymphoblastic leukemia (ALL);
- bone marrow transplant (BMT);
- immune reconstitution;
- stem cell transplantation (SCT);
- vitreoretinal surgery
Purpose: To describe the treatment of cytomegalovirus (CMV) retinitis with intravitreal sustain-release ganciclovir devices in a 16-year-old patient in third remission of acute lymphoblastic leukemia after stem cell transplantation.
Methods: The patient received a stem cell transplant from an unrelated bone marrow donor after which he contracted a serious CMV infection manifested in the lungs and retinae. His immune system at this time was almost completely depleted. Implantation of a sustained-release ganciclovir device was performed in both eyes when retinitis progressed in spite of aggressive antiviral intravenous treatment.
Results: No per- or postoperative complications were noted. Infiltrates, hemorrhages and macular edema present preoperatively dissolved over a period of six months. The final visual acuity was 1.0 in both eyes. The patients immune system and lung function slowly recovered during the same time period.
Conclusions: The intravitreal ganciclovir implant provides safe and effective therapy against CMV retinitis, and should be considered in patients acquiring the infection after stem cell transplantation.